Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Core Insights - The JASMINE study achieved its primary endpoint and key secondary and exploratory endpoints, indicating the potential of nipocalimab for steroid sparing in systemic lupus erythematosus (SLE) [2][4] - Johnson & Johnson plans to initiate a Phase 3 program for nipocalimab based on the positive topline results from the Phase 2b study [2][5] Company Overview - Johnson & Johnson is focused on innovative medicine and aims to address complex diseases through advanced healthcare solutions [11] - The company has a strong commitment to developing treatments that are safe, tolerable, and capable of reducing disease activity while preserving immune function [5] Industry Context - SLE is a chronic autoimmune disease affecting approximately 3 to 5 million people globally, with around 450,000 cases in the U.S. [3][9] - The disease significantly impacts health-related quality of life, with symptoms including severe fatigue, joint pain, and rashes [9] - There is a critical need for new immunoselective therapies due to complications associated with long-term steroid use in SLE patients [5]